Oncternal Therapeutics (ONCT) Stock Forecast, Price Target & Predictions
ONCT Stock Forecast
Oncternal Therapeutics stock forecast is as follows: an average price target of $28.00 (represents a 1791.89% upside from ONCT’s last price of $1.48) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
ONCT Price Target
The average price target for Oncternal Therapeutics (ONCT) is $28.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $28.00. This represents a potential 1791.89% upside from ONCT's last price of $1.48.
ONCT Analyst Ratings
According to 6 Wall Street analysts, Oncternal Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ONCT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Oncternal Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 15, 2024 | Raghuram Selvaraju | H.C. Wainwright | $28.00 | $9.40 | 197.87% | 1791.89% |
The latest Oncternal Therapeutics stock forecast, released on Apr 15, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $28.00, which represents a 197.87% increase from the stock price at the time of the forecast ($9.40), and a 1791.89% increase from ONCT last price ($1.48).
Oncternal Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $28.00 |
| Last Closing Price | $1.48 | $1.48 | $1.48 |
| Upside/Downside | -100.00% | -100.00% | 1791.89% |
In the current month, the average price target of Oncternal Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Oncternal Therapeutics's last price of $1.48. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jan 29, 2024 | Barclays | Buy | Buy | Hold |
| Dec 04, 2023 | Brookline Capital | - | Buy | Upgrade |
| Sep 18, 2023 | H.C. Wainwright | - | Buy | Upgrade |
| Mar 22, 2023 | Oppenheimer | Outperform | Outperform | Hold |
| Dec 22, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
| Feb 24, 2022 | BTIG | - | Buy | Initialise |
Oncternal Therapeutics's last stock rating was published by H.C. Wainwright on Apr 15, 2024. The company gave ONCT a "Buy" rating, the same as its previous rate.
Oncternal Therapeutics Financial Forecast
Oncternal Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.14M | $2.13M | $883.00K | $748.00K | $1.59M | $585.00K | $1.83M | $9.29M | $56.58M | $3.63M | - | - | - | - |
| Avg Forecast | $200.00K | $200.00K | $200.00K | $200.00K | $275.00K | $275.00K | $212.50K | $183.33K | $128.00K | $125.00K | $170.83K | $166.67K | $331.50K | $325.00K | $459.00K | $525.00K | $1.06M | $1.30M | $1.09M | $1.11M | $587.50K | $623.00K | $1.63M | $13.56M | $54.26M | $4.30M | $3.73M | $1.97M | $1.19M | $677.59K |
| High Forecast | $200.00K | $200.00K | $200.00K | $200.00K | $275.00K | $275.00K | $212.75K | $183.50K | $195.76K | $125.00K | $170.83K | $166.67K | $331.50K | $325.00K | $459.00K | $525.00K | $1.06M | $1.30M | $1.09M | $1.11M | $587.50K | $623.00K | $1.95M | $16.27M | $65.11M | $5.16M | $4.47M | $2.36M | $1.43M | $813.11K |
| Low Forecast | $200.00K | $200.00K | $200.00K | $200.00K | $275.00K | $275.00K | $212.25K | $183.17K | $75.29K | $125.00K | $170.83K | $166.67K | $331.50K | $325.00K | $459.00K | $525.00K | $1.06M | $1.30M | $1.09M | $1.11M | $587.50K | $623.00K | $1.30M | $10.85M | $43.41M | $3.44M | $2.98M | $1.58M | $952.63K | $542.07K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 | 10 | 20 | 12 | 17 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.98% | 1.64% | 0.81% | 0.67% | 2.70% | 0.94% | 1.13% | 0.69% | 1.04% | 0.84% | - | - | - | - |
Oncternal Therapeutics's average Quarter revenue forecast for Mar 22 based on 1 analysts is $525.00K, with a low forecast of $525.00K, and a high forecast of $525.00K. ONCT's average Quarter revenue forecast represents a -116.70% decrease compared to the company's last Quarter revenue of $-3.14M (Dec 21).
Oncternal Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 | 10 | 20 | 12 | 17 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-10.39M | $-9.54M | $-12.14M | $-11.91M | $-11.32M | $-11.79M | $-9.91M | $-8.07M | $-9.63M | $-7.68M | $-5.95M | $-2.56M | $-4.39M | $-10.87M | $-2.28M | $44.78M | $-11.04M | - | - | - | - |
| Avg Forecast | $-120.00K | $-120.00K | $-120.00K | $-120.00K | $-165.00K | $-165.00K | $-127.50K | $-110.00K | $-76.80K | $-75.00K | $-102.50K | $-100.00K | $-198.90K | $-195.00K | $-275.40K | $-9.91M | $-634.08K | $-778.80K | $-653.25K | $-4.76M | $-352.50K | $-5.57M | $-9.66M | $-3.32M | $42.94M | $-13.07M | $-12.64M | $-11.08M | $-9.80M | $-9.05M |
| High Forecast | $-120.00K | $-120.00K | $-120.00K | $-120.00K | $-165.00K | $-165.00K | $-127.35K | $-109.90K | $-45.18K | $-75.00K | $-102.50K | $-100.00K | $-198.90K | $-195.00K | $-275.40K | $-7.93M | $-634.08K | $-778.80K | $-653.25K | $-3.81M | $-352.50K | $-4.45M | $-7.73M | $-2.66M | $51.53M | $-10.46M | $-10.12M | $-8.87M | $-7.84M | $-7.24M |
| Low Forecast | $-120.00K | $-120.00K | $-120.00K | $-120.00K | $-165.00K | $-165.00K | $-127.65K | $-110.10K | $-117.46K | $-75.00K | $-102.50K | $-100.00K | $-198.90K | $-195.00K | $-275.40K | $-11.89M | $-634.08K | $-778.80K | $-653.25K | $-5.71M | $-352.50K | $-6.68M | $-11.59M | $-3.99M | $34.35M | $-15.68M | $-15.17M | $-13.30M | $-11.76M | $-10.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | 138.53% | 93.12% | 121.43% | 59.90% | 58.08% | 42.83% | 1.00% | 12.73% | 12.37% | 11.76% | 1.25% | 7.25% | 0.79% | 1.13% | 0.69% | 1.04% | 0.84% | - | - | - | - |
9 analysts predict ONCT's average Quarter EBITDA for Mar 11 to be $-3.32M, with a high of $-2.66M and a low of $-3.99M. This is -107.42% lower than Oncternal Therapeutics's previous annual EBITDA (Mar 10) of $44.78M.
Oncternal Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 | 10 | 20 | 12 | 17 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | $-9.86M | $-8.97M | $-11.48M | $-10.88M | $-10.72M | $-11.63M | $-9.89M | $-8.07M | $-9.63M | $-7.68M | $-5.95M | $-2.56M | $-4.39M | $-11.08M | $-2.60M | $44.34M | $-11.30M | - | - | - | - |
| Avg Forecast | $-5.71M | $-5.59M | $-6.13M | $-6.78M | $-8.76M | $-9.46M | $-8.98M | $-8.52M | $-9.13M | $-8.58M | $-9.59M | $-11.76M | $-12.56M | $-14.09M | $-13.54M | $-9.90M | $-14.56M | $-9.47M | $-8.14M | $-4.76M | $-10.66M | $-5.57M | $-9.85M | $-3.79M | $42.52M | $-13.38M | $-10.62M | $-9.67M | $-9.77M | $-8.96M |
| High Forecast | $-5.71M | $-5.59M | $-6.13M | $-6.78M | $-8.76M | $-9.46M | $-8.98M | $-8.52M | $-6.71M | $-8.58M | $-9.59M | $-11.76M | $-12.56M | $-14.09M | $-13.54M | $-7.92M | $-14.56M | $-9.47M | $-8.14M | $-3.81M | $-10.66M | $-4.45M | $-7.88M | $-3.03M | $51.03M | $-10.71M | $-8.50M | $-7.73M | $-7.81M | $-7.16M |
| Low Forecast | $-5.71M | $-5.59M | $-6.13M | $-6.78M | $-8.76M | $-9.46M | $-8.98M | $-8.52M | $-10.25M | $-8.58M | $-9.59M | $-11.76M | $-12.56M | $-14.09M | $-13.54M | $-11.88M | $-14.56M | $-9.47M | $-8.14M | $-5.71M | $-10.66M | $-6.68M | $-11.82M | $-4.54M | $34.02M | $-16.06M | $-12.74M | $-11.60M | $-11.72M | $-10.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.15% | 0.94% | 0.98% | 0.87% | 0.76% | 0.86% | 1.00% | 0.55% | 1.02% | 0.94% | 1.25% | 0.24% | 0.79% | 1.13% | 0.69% | 1.04% | 0.84% | - | - | - | - |
Oncternal Therapeutics's average Quarter net income forecast for Mar 11 is $-3.79M, with a range of $-4.54M to $-3.03M. ONCT's average Quarter net income forecast represents a -108.54% decrease compared to the company's last Quarter net income of $44.34M (Mar 10).
Oncternal Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 | 10 | 20 | 12 | 17 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | $3.09M | $3.07M | $3.31M | $3.29M | $3.27M | $3.23M | $3.68M | $2.62M | $2.80M | $3.38M | $2.79M | $1.46M | $1.93M | $2.81M | $4.68M | $4.51M | $6.54M | - | - | - | - |
| Avg Forecast | $1.34M | $1.34M | $1.34M | $1.34M | $1.84M | $1.84M | $1.42M | $1.23M | $856.09K | $836.03K | $1.14M | $1.11M | $2.22M | $2.17M | $3.07M | $3.51M | $7.07M | $8.68M | $7.28M | $7.46M | $3.93M | $4.17M | $10.87M | $6.83M | $4.32M | $28.76M | $3.54M | $13.17M | $7.96M | $4.53M |
| High Forecast | $1.34M | $1.34M | $1.34M | $1.34M | $1.84M | $1.84M | $1.42M | $1.23M | $1.31M | $836.03K | $1.14M | $1.11M | $2.22M | $2.17M | $3.07M | $3.51M | $7.07M | $8.68M | $7.28M | $7.46M | $3.93M | $4.17M | $13.05M | $8.20M | $5.19M | $34.51M | $4.25M | $15.81M | $9.56M | $5.44M |
| Low Forecast | $1.34M | $1.34M | $1.34M | $1.34M | $1.84M | $1.84M | $1.42M | $1.23M | $503.58K | $836.03K | $1.14M | $1.11M | $2.22M | $2.17M | $3.07M | $3.51M | $7.07M | $8.68M | $7.28M | $7.46M | $3.93M | $4.17M | $8.70M | $5.47M | $3.46M | $23.01M | $2.83M | $10.54M | $6.37M | $3.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.70% | 2.69% | 2.97% | 1.48% | 1.50% | 1.05% | 1.05% | 0.37% | 0.32% | 0.46% | 0.37% | 0.37% | 0.46% | 0.26% | 0.69% | 1.04% | 0.23% | - | - | - | - |
Oncternal Therapeutics's average Quarter SG&A projection for Dec 23 is $856.09K, based on 3 Wall Street analysts, with a range of $503.58K to $1.31M. The forecast indicates a -72.33% fall compared to ONCT last annual SG&A of $3.09M (Sep 23).
Oncternal Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 | 10 | 20 | 12 | 17 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.17 | $-0.15 | $-0.20 | $-0.19 | $-0.20 | $-0.23 | $-0.20 | $-0.16 | $-0.19 | $-0.16 | $-0.12 | $-0.09 | $-0.22 | $-12.60 | $-3.50 | $85.40 | $-21.70 | - | - | - | - |
| Avg Forecast | $-1.93 | $-1.89 | $-2.07 | $-2.29 | $-2.96 | $-3.19 | $-3.03 | $-2.88 | $-3.08 | $-2.90 | $-3.24 | $-3.97 | $-4.24 | $-4.76 | $-4.57 | $-4.04 | $-4.92 | $-3.20 | $-2.75 | $-2.00 | $-3.60 | $-6.00 | $-1.44 | $-1.93 | $11.24 | $-4.50 | $-2.50 | $-3.38 | $-3.10 | $-3.60 |
| High Forecast | $-1.93 | $-1.89 | $-2.07 | $-2.29 | $-2.96 | $-3.19 | $-3.03 | $-2.88 | $-2.27 | $-2.90 | $-3.24 | $-3.97 | $-4.24 | $-4.76 | $-4.57 | $-4.04 | $-4.92 | $-3.20 | $-2.75 | $-2.00 | $-3.60 | $-6.00 | $-1.15 | $-1.54 | $13.49 | $-3.60 | $-2.00 | $-2.70 | $-2.48 | $-2.88 |
| Low Forecast | $-1.93 | $-1.89 | $-2.07 | $-2.29 | $-2.96 | $-3.19 | $-3.03 | $-2.88 | $-3.46 | $-2.90 | $-3.24 | $-3.97 | $-4.24 | $-4.76 | $-4.57 | $-4.04 | $-4.92 | $-3.20 | $-2.75 | $-2.00 | $-3.60 | $-6.00 | $-1.73 | $-2.31 | $8.99 | $-5.40 | $-3.00 | $-4.06 | $-3.72 | $-4.32 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.06% | 0.05% | 0.05% | 0.04% | 0.04% | 0.05% | 0.05% | 0.03% | 0.06% | 0.06% | 0.06% | 0.02% | 0.04% | 8.75% | 1.81% | 7.60% | 4.82% | - | - | - | - |
According to 9 Wall Street analysts, Oncternal Therapeutics's projected average Quarter EPS for Mar 11 is $-1.93, with a low estimate of $-2.31 and a high estimate of $-1.54. This represents a -102.26% decrease compared to ONCT previous annual EPS of $85.40 (Mar 10).
Oncternal Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ADTX | Aditxt | $0.49 | $160.00 | 32553.06% | - |
| ONCT | Oncternal Therapeutics | $1.48 | $28.00 | 1791.89% | Buy |
| PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
| CTMX | CytomX Therapeutics | $1.01 | $5.77 | 471.29% | Buy |
| NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
| TIL | Instil Bio | $27.63 | $78.25 | 183.21% | Hold |
| KZR | Kezar Life Sciences | $7.09 | $17.50 | 146.83% | Buy |
| ASMB | Assembly Biosciences | $16.98 | $35.50 | 109.07% | Buy |
| ADVM | Adverum Bio | $7.54 | $15.50 | 105.57% | Buy |
| ABSI | Absci | $4.00 | $6.00 | 50.00% | Buy |
ONCT Forecast FAQ
Is Oncternal Therapeutics a good buy?
Yes, according to 6 Wall Street analysts, Oncternal Therapeutics (ONCT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of ONCT's total ratings.
What is ONCT's price target?
Oncternal Therapeutics (ONCT) average price target is $28 with a range of $28 to $28, implying a 1791.89% from its last price of $1.48. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Oncternal Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ONCT stock, the company can go up by 1791.89% (from the last price of $1.48 to the average price target of $28), up by 1791.89% based on the highest stock price target, and up by 1791.89% based on the lowest stock price target.
Can Oncternal Therapeutics stock reach $2?
ONCT's average twelve months analyst stock price target of $28 supports the claim that Oncternal Therapeutics can reach $2 in the near future.
What are Oncternal Therapeutics's analysts' financial forecasts?
Oncternal Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $945.83K (high $946.25K, low $945.42K), average EBITDA is $-567K (high $-567K, low $-568K), average net income is $-35.715M (high $-35.715M, low $-35.715M), average SG&A $6.33M (high $6.33M, low $6.32M), and average EPS is $-12.066 (high $-12.066, low $-12.066). ONCT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $800K (high $800K, low $800K), average EBITDA is $-480K (high $-480K, low $-480K), average net income is $-24.213M (high $-24.213M, low $-24.213M), average SG&A $5.35M (high $5.35M, low $5.35M), and average EPS is $-8.18 (high $-8.18, low $-8.18).
Did the ONCT's actual financial results beat the analysts' financial forecasts?
Based on Oncternal Therapeutics's last annual report (Dec 2021), the company's revenue was $4.32M, which missed the average analysts forecast of $4.56M by -5.34%. Apple's EBITDA was $-31.366M, beating the average prediction of $-6.825M by 359.61%. The company's net income was $-31.3M, missing the average estimation of $-36.934M by -15.25%. Apple's SG&A was $11.6M, missing the average forecast of $30.49M by -61.97%. Lastly, the company's EPS was $-0.63, missing the average prediction of $-12.87 by -95.10%. In terms of the last quarterly report (Dec 2021), Oncternal Therapeutics's revenue was $-3.144M, missing the average analysts' forecast of $1.06M by -397.50%. The company's EBITDA was $-8.073M, beating the average prediction of $-634K by 1173.18%. Oncternal Therapeutics's net income was $-8.066M, missing the average estimation of $-14.563M by -44.61%. The company's SG&A was $2.62M, missing the average forecast of $7.07M by -62.96%. Lastly, the company's EPS was $-0.16, missing the average prediction of $-4.92 by -96.75%